Carvedilol
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Carvedilol is a unique third-generation beta-blocker that combines non-selective beta-blockade with alpha-1 receptor antagonism and antioxidant properties. The COPERNICUS trial demonstrated a 35% reduction in mortality in severe heart failure, establishing it as a cornerstone of HF therapy.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Carvedilol is a unique third-generation beta-blocker that combines non-selective beta-blockade with alpha-1 receptor antagonism and antioxidant properties. NutriStack rates the supporting evidence as strong. Common adult dosing is 3.125–50 mg twice daily (IR) or 10–80 mg once daily (CR); HF target: 25 mg BID (<85 kg) or 50 mg BID (≥85 kg) (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete coq10. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: reduces mortality in heart failure (copernicus, comet trials), provides vasodilation via alpha-1 blockade, improves insulin sensitivity relative to other beta-blockers. 10 sources indexed (2014–2024), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Non-selectively blocks beta-1 and beta-2 adrenergic receptors and additionally blocks alpha-1 receptors. Alpha-1 blockade provides vasodilation and reduces peripheral resistance without reflex tachycardia (due to concurrent beta-blockade). Also has antioxidant and anti-proliferative properties that may confer additional cardioprotection.2
Dosing & protocol.
Should be taken with food to slow absorption and reduce risk of orthostatic hypotension
What it depletes.
Nutrients this medication can lower over time, and what to replace.
CoQ10
MildChronic beta-blocker therapy has been associated with lower tissue CoQ10 status and reduced mitochondrial electron transport support.
Full safety detail.
Side effects
- Dizziness and orthostatic hypotension
- Bradycardia
- Fatigue
- Weight gain
- Diarrhea
- Visual disturbances
- Edema
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Which should you choose for post operative atrial fibrillation, carvedilol or metoprolol? A systemic review and meta-analysisPMIDAbouzid MR, Vyas A, Eldahtoury S et al. · Current problems in cardiology · 2024
Abouzid MR, Vyas A, Eldahtoury S et al.. Which should you choose for post operative atrial fibrillation, carvedilol or metoprolol? A systemic review and meta-analysis. Current problems in cardiology. 2024
- 2Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilolPMIDHuang S, Zhao Q, Yang ZG et al. · Heart failure reviews · 2019
Huang S, Zhao Q, Yang ZG et al.. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart failure reviews. 2019
- 3Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced CardiotoxicityPMIDKheiri B, Abdalla A, Osman M et al. · The American journal of cardiology · 2018
Kheiri B, Abdalla A, Osman M et al.. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. The American journal of cardiology. 2018
- 4Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysisPMIDLi T, Ke W, Sun P et al. · BMJ open · 2016
Li T, Ke W, Sun P et al.. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ open. 2016
- 5Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysisPMIDAguilar-Olivos N, Motola-Kuba M, Candia R et al. · Annals of hepatology · 2014
Aguilar-Olivos N, Motola-Kuba M, Candia R et al.. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis. Annals of hepatology. 2014
Reference material
5- 6Packer M et al. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001.Source linkedPMID
- 7Poole-Wilson PA et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003.Source linkedPMID
- 8Pannala S et al. NSBBs, EBL or Combined Therapy for High-Risk Varices: Systematic Review and Meta-Analysis. Liver Int. 2025.Source linkedPMID
- 9Villanueva C, Torres F, Sarin SK et al.. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. Journal of hepatology. 2022Source linkedPMID
- 10Alvarado-Tapias E, Brujats A, Puente A et al.. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial. Hepatology (Baltimore, Md.). 2025Source linkedPMID
Common questions.
Quick answers about Carvedilol, drawn from the data on this page.
What is Carvedilol?
Carvedilol is a unique third-generation beta-blocker that combines non-selective beta-blockade with alpha-1 receptor antagonism and antioxidant properties. The COPERNICUS trial demonstrated a 35% reduction in mortality in severe heart failure, establishing it as a cornerstone of HF therapy.
What is Carvedilol used for?
Commonly cited benefits of Carvedilol include: Reduces mortality in heart failure (COPERNICUS, COMET trials); Provides vasodilation via alpha-1 blockade; Improves insulin sensitivity relative to other beta-blockers; Antioxidant properties. NutriStack rates the overall evidence as strong.
What is a typical dose of Carvedilol?
A typical adult dose of Carvedilol is 3.125–50 mg twice daily (IR) or 10–80 mg once daily (CR); HF target: 25 mg BID (<85 kg) or 50 mg BID (≥85 kg) (as prescribed by your physician). The commonly recommended form is Oral tablet (immediate-release) or extended-release capsule. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Carvedilol?
Reported side effects include dizziness and orthostatic hypotension, bradycardia, fatigue, weight gain, diarrhea, visual disturbances. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Carvedilol?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Carvedilol in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.